Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland

Małgorzata Kanarkiewicz, T. Szczęsny, J. Krysiński, A. Buciński, J. Kowalewski, Zbigniew Pawłowicz
{"title":"Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland","authors":"Małgorzata Kanarkiewicz, T. Szczęsny, J. Krysiński, A. Buciński, J. Kowalewski, Zbigniew Pawłowicz","doi":"10.5114/wo.2015.56656","DOIUrl":null,"url":null,"abstract":"Aim of the study To determine the cost-effectiveness of lung cancer (LC) screening with low-dose computerised tomography of the chest, as compared to an approach without screening, reimbursed today by the National Health Fund (NHF) in Poland. Material and methods In order to analyse the current costs of diagnostic and therapeutic procedures of a model LC patient treated today, a model group consisting of 199 consecutive patients diagnosed and treated in the Oncology Centre in Bydgoszcz, Poland from January 2007 to April 2010 was used. The number and type of performed procedures in this group was obtained from the Polish Register of Neoplasms and the NHF. Only direct medical costs were analysed. To calculate the total costs of screening, diagnostics, and treatment of the hypothetical LC patient who would have cancer diagnosed with screening CT, data from the literature and costs calculated for the model group were used. Prices of procedures were obtained from the price list of the NHF on 30 April 2010 and did not change from that time until June 2014. One-way sensitivity analysis was performed. Results The average cost per LC patient, diagnosed and treated without screening, is 5567.50 EUR, and median LC-specific survival is one year. In the hypothetical LC patient with cancer diagnosed by screening, the average cost is 13689.35 EUR per LC patient, with a median LC-specific survival of at least seven years. A calculated incremental cost-effectiveness ratio (ICER) is 1353.64 EUR/year of life gained. Conclusions Lung cancer screening with low-dose CT would be highly cost-effective in Poland.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"480 - 486"},"PeriodicalIF":0.0000,"publicationDate":"2015-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2015.56656","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Aim of the study To determine the cost-effectiveness of lung cancer (LC) screening with low-dose computerised tomography of the chest, as compared to an approach without screening, reimbursed today by the National Health Fund (NHF) in Poland. Material and methods In order to analyse the current costs of diagnostic and therapeutic procedures of a model LC patient treated today, a model group consisting of 199 consecutive patients diagnosed and treated in the Oncology Centre in Bydgoszcz, Poland from January 2007 to April 2010 was used. The number and type of performed procedures in this group was obtained from the Polish Register of Neoplasms and the NHF. Only direct medical costs were analysed. To calculate the total costs of screening, diagnostics, and treatment of the hypothetical LC patient who would have cancer diagnosed with screening CT, data from the literature and costs calculated for the model group were used. Prices of procedures were obtained from the price list of the NHF on 30 April 2010 and did not change from that time until June 2014. One-way sensitivity analysis was performed. Results The average cost per LC patient, diagnosed and treated without screening, is 5567.50 EUR, and median LC-specific survival is one year. In the hypothetical LC patient with cancer diagnosed by screening, the average cost is 13689.35 EUR per LC patient, with a median LC-specific survival of at least seven years. A calculated incremental cost-effectiveness ratio (ICER) is 1353.64 EUR/year of life gained. Conclusions Lung cancer screening with low-dose CT would be highly cost-effective in Poland.
波兰低剂量胸部计算机断层扫描肺癌筛查的成本-效果分析
研究的目的是确定低剂量胸部计算机断层扫描肺癌(LC)筛查的成本效益,与不进行筛查的方法相比,波兰国家卫生基金(NHF)今天报销。为了分析目前治疗的模型LC患者的诊断和治疗程序的当前成本,使用了2007年1月至2010年4月在波兰Bydgoszcz肿瘤中心连续诊断和治疗的199例患者组成的模型组。本组手术的数量和类型来自波兰肿瘤登记处和NHF。只分析了直接医疗费用。为了计算通过筛查CT诊断出癌症的假设LC患者的筛查、诊断和治疗的总费用,使用文献数据和模型组计算的费用。程序价格从2010年4月30日NHF的价目表中获得,从那时起直到2014年6月没有变化。进行单因素敏感性分析。结果每位LC患者(未经筛查诊断和治疗)的平均成本为5567.50欧元,中位LC特异性生存期为1年。在假设的通过筛查诊断出癌症的LC患者中,每个LC患者的平均费用为13689.35欧元,中位LC特异性生存期至少为7年。计算出的增量成本效益比(ICER)为1353.64欧元/年的寿命延长。结论低剂量CT肺癌筛查在波兰具有很高的成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信